Background The objective of this study was to estimate the annual incidence rates of herpes zoster (HZ) and postherpetic neuralgia (PHN) among individuals aged ≥19 years and the proportion of individuals who received HZ vaccination among individuals aged ≥50 years. Methods This observational cohort study was conducted using administrative claims data from HealthVerity and included insured individuals across the United States (US). Crude and US age- and sex-standardized incidence rates of HZ and PHN were calculated from 1/1/2019 to 5/31/2022, by calendar year, in persons aged ≥19 years. Outcomes were defined as ≥1 International Classification of Diseases-10 diagnosis code for HZ or PHN. Analyses were stratified by age, sex, and immunocompromised status. Among those aged ≥50 years, the proportion of persons who received 1 or 2 doses of recombinant zoster vaccine (Shingrix) or 1 dose of Zostavax was calculated. Results Standardized annual incidence rates from 2019 to 2021 were 542–685 per 100,000 person-years for HZ and 35–38 per 100,000 person-years for PHN. Rates were highest among females, older adults, and immunocompromised individuals. From 1/1/2019 to 5/31/2022, 4.3% and 9.0% of individuals aged ≥50 years received 1 and 2 doses of Shingrix, respectively, and 0.2% received 1 dose of Zostavax. Conclusions In this US claims database analysis, HZ and PHN were more frequent among older adults, females, and immunocompromised individuals. Between 1/1/2019 and 5/31/2022, 9% of persons aged ≥50 years received 2 doses of the Shingrix vaccine. Greater efforts are needed to increase vaccine uptake against HZ, especially for those at highest risk.

中文翻译：

---

美国行政索赔数据库中带状疱疹和带状疱疹后神经痛的发病率以及带状疱疹疫苗接种情况

背景 本研究的目的是估计 19 岁以上人群中带状疱疹 (HZ) 和带状疱疹后神经痛 (PHN) 的年发病率以及 50 岁以上人群中接受 HZ 疫苗接种的人数比例。方法 这项观察性队列研究是使用 HealthVerity 的行政索赔数据进行的，纳入了美国 (US) 各地的参保个人。按日历年计算了 2019 年 1 月 1 日至 2022 年 5 月 31 日期间 19 岁以上人群的 HZ 和 PHN 的粗略和美国年龄和性别标准化发病率。结果定义为≥1 个国际疾病分类-10 的 HZ 或 PHN 诊断代码。分析按年龄、性别和免疫功能低下状态进行分层。在年龄≥50岁的人群中，计算了接受1或2剂重组带状疱疹疫苗（Shingrix）或1剂Zostavax的人数比例。结果 2019 年至 2021 年，HZ 的标准化年发病率为每 10 万人年 542–685 例，PHN 的标准化年发病率为每 10 万人年 35–38 例。女性、老年人和免疫功能低下者的发病率最高。从2019年1月1日至2022年5月31日，年龄≥50岁的个体中有4.3%和9.0%分别接受了1剂和2剂Shingrix，0.2%接受了1剂Zostavax。结论 在美国理赔数据库分析中，带状疱疹和 PHN 在老年人、女性和免疫功能低下的个体中更为常见。 2019 年 1 月 1 日至 2022 年 5 月 31 日期间，年龄≥50 岁的人中有 9% 接种了 2 剂 Shingrix 疫苗。需要付出更大的努力来提高带状疱疹疫苗的接种率，特别是对于那些风险最高的人群。